Invivyd, Inc. — Form 8-K
Filed September 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Invivyd announced positive topline results from the LIBERTY Phase 3 study (N=210, 1:1:1 randomization) comparing VYD2311 (250 mg single dose) to mRNA COVID-19 vaccine (Comirnaty) and combination therapy. VYD2311 monotherapy demonstrated statistically superior safety/tolerability: 56.5% vs. 91.4% adverse events at 6 days (p<0.0001); 44.1% vs. 68.1% systemic AEs (p=0.008); 60.9% vs. 91.4% at 56 days (p<0.0001). VYD2311+mRNA combination showed 2.5× higher neutralizing titers with no immunologic interference. Company plans BLA submission via FDA Accelerated Approval pathway; DECLARATION pivotal trial safety/immunogenicity data expected October 2026; clinical efficacy data to remain blinded post-approval pending event accrual.
Why this rating
Lead asset clears key Phase 3 safety hurdle with superior profile vs. standard-of-care; positions $51M-cap biotech for regulatory filing on 2,400-patient Phase 3 dataset. Material near-term catalyst offsetting development risk; meaningful for clinical validation but approval/commercialization remain uncertain.
Price action (we called it positive)
before filing · preread $0.97 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.